Wave Life Sciences Ltd
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
WVE$3.41-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| For the Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities | ||
| Net loss | $(57,513) | $(161,823) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization of right-of-use assets | 4,206 | 3,540 |
| Depreciation of property and equipment | 5,000 | 6,574 |
| Share-based compensation expense | 9,795 | 17,194 |
| Loss on disposal of property and equipment | — | 12 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (21,086) | — |
| Prepaid expenses | (1,980) | (1,348) |
| Other assets | (2,010) | 3,394 |
| Accounts payable | (3,761) | 9,348 |
| Accrued expenses and other current liabilities | (724) | 2,691 |
| Deferred revenue | 54,328 | (3,245) |
| Operating lease liabilities | (5,496) | (4,308) |
| Other non-current liabilities | (190) | 190 |
| Net cash used in operating activities | (19,431) | (127,781) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (1,115) | (1,361) |
| Proceeds from the sale of property and equipment | — | 106 |
| Purchase of short-term investments | — | (75,044) |
| Proceeds from the maturity of short-term investments | — | 75,044 |
| Net cash used in investing activities | (1,115) | (1,255) |
| Cash flows from financing activities | ||
| Proceeds from issuance of ordinary shares, net of offering costs | 93,574 | 51,220 |
| Proceeds from issuance pre-funded warrants, net of offering costs | — | 14,268 |
| Proceeds from issuance of ordinary shares pursuant to the GSK Collaboration Agreement | 34,623 | — |
| Proceeds from issuance of ordinary shares pursuant to the at-the-market equity program, net | 3,080 | 1,105 |
| Proceeds from the exercise of share options | 509 | 223 |
| Proceeds from the ESPP | 748 | 372 |
| Net cash provided by financing activities | 132,534 | 67,188 |
| Effect of foreign exchange rates on cash | (95) | (210) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 111,893 | (62,058) |
| Cash, cash equivalents and restricted cash, beginning of period | 92,157 | 154,215 |
| Cash, cash equivalents and restricted cash, end of period | $204,050 | $92,157 |
| Supplemental disclosure of cash flow information: | ||
| Offering costs in accounts payable at period end | $210 | $— |
| Increase in operating lease right-of-use assets and lease liabilities related to new lease | $— | $12,006 |
Wave Life Sciences Ltd.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.